PAMIDRONATO DISODICO MAYNE ® - Pamidronic acid

PAMIDRONATO DISODICO MAYNE ® is a drug based on pamidronic acid sodium salt

THERAPEUTIC GROUP: Drugs affecting bone metabolism - Bisphosphonates

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications PAMIDRONATO DISODICO MAYNE ® - Pamidronic acid

PAMIDRONATO DISODICO MAYNE ® is used in hospitals for the treatment of bone diseases associated with cancer, such as neoplastic hypercalcemia, bone metastases from multiple myeloma or breast carcinoma and osteosarcoma.

Mode of action PAMIDRONATO DISODICO MAYNE ® - Pamidronic acid

Pamidronic acid, active principle of PAMIDRONATO DISODICO MAYNE ®, like other bisphosphonates, has a selective action on bone tissue, concentrating mainly at the level of active resorption sites and modulating the osteoriasorption activity of osteoclasts.

Through molecular mechanisms not yet characterized, pamidronate is also able to inhibit the differentiation of bone cells towards the osteoclastic line, thus protecting this tissue from excessive degradation present in these pathologies.

The aforementioned action also has repercussions on some metabolic parameters, indicative of the condition of bone health, such as calcemia and alkaline phosphatase, whose concentrations generally fall within the normal ranges.

This type of treatment has also proved effective in reducing the intense bone pain that often affects these patients.

Studies carried out and clinical efficacy

1. PAMIDRONIC ACID AND APOPTOSIS OF NEOPLASTIC CELLS

Experimental study that attempts to best characterize the molecular activity of pamidronic acid on neoplastic cells. This interesting work demonstrates how the aforementioned active ingredient can prevent the onset of prostate cancer metastases by inhibiting the expression of antiapoptotic genes in neoplastic cells

2. BIOMARKERS PREDICTIVES FOR THE ANALGESIC EFFECT OF PAMIDRONATE

Work that associates blood concentrations of some biochemical markers of bone metabolism such as osteoprotegerin and collagen of the first type with the analgesic response to pamidronate. This binding could be important in monitoring the analgesic efficacy of bisphosphonate treatment.

3. MOLECULAR MECHANISMS OF PAMIDRONATE ACTIVITY

A further experimental study demonstrating that pamidronate has an anti-proliferative, apoptotic and antimigratory potential on hepatic carcinoma cells. The characterization of the molecular activity of this drug could be important for pharmacological research.

Method of use and dosage

PAMIDRONATO DISODICO MAYNE ®

Powder and solvent for solution for infusion of 15 mg, 30 mg, 60 mg and 90 mg of pamidronate disodium:

the therapeutic scheme relating to the use of pamidronic acid must be established by the hospital doctor at the time of admission of the patient.

It is useful to remember how the use of this active ingredient is reserved for patients admitted to hospital facilities, and how it is absolutely necessary to avoid bolus administration given the important side effects on patient health.

Warnings PAMIDRONATO DISODICO MAYNE ® - Pamidronic acid

Although pamidronic acid is well tolerated when used according to conventional therapeutic schemes, the administration of this drug must necessarily take place in a hospital environment and under the supervision of an experienced specialist doctor.

Patients with impaired renal function or those suffering from heart disease or familiarity with the aforementioned morbid conditions and subjected to therapy with PAMIDRONATO DISODICO MAYNE ® should undergo periodic checks to ascertain the overall health status of the patient and the specific health of the organs concerned, given the ability of pamidronate to aggravate the related clinical pictures.

Contextual supplementation with Vitamin D and Calcium in patients undergoing treatment with pamidronic acid and not affected by hypercalcemia, could be useful to safeguard the blood concentrations of this element and avoid the onset of pathological conditions such as tetany or paresthesia.

Therefore monitoring of blood concentrations of calcium, phosphorus, magnesium and potassium could be important to avoid the appearance of more serious side effects.

The increased risk of osteonecrosis of the jaw in patients receiving AREDIA ® should be seriously considered before any dental treatment.

PREGNANCY AND BREASTFEEDING

The use of PAMIDRONATO DISODICO MAYNE ® is contraindicated during pregnancy and lactation due to the different experimental studies present in the literature, which show the ability of this bisphosphonate to pass through both placental and mammary filters, thus achieving significant concentrations both in the fetus that in the infant.

Interactions

At the moment active ingredients capable of varying the pharmacokinetic and pharmacological properties of pamidronic acid are not known.

A very important note for the cancer patient is the absence of additional side effects related to the simultaneous intake of pamidronate sodium and chemotherapy.

Contraindications PAMIDRONATO DISODICO MAYNE ® - Pamidronic acid

PAMIDRONATO DISODICO MAYNE ® contraindicated in case of renal insufficiency and hypersensitivity to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

The side effects described following the use of pamidronate are generally mild and transient, and only rarely such as to require suspension of treatment.

Anemia, thrombocytopenia, lymphocytopenia, hypokalemia, hypomagnesemia, headache, insomnia, drowsiness, conjunctivitis, hypertension, dermal rash and allergic manifestations of nature, increased creatininemia, reduced renal function, fever and flu-like symptoms, atralgia and myalgia are the most frequently reported adverse reactions along with hypocalcemia, responsible for paresthesia and tetany.